Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;8(2):109-110.
doi: 10.5152/eurjrheum.2020.20080.

bDMARDs retention rate in the biosimilar era: A real-life monocentric study

Andrea Becciolini  1 , Federica Lumetti  2 , Eleonora Di Donato  1 , Salvatore Giordano  1 , Daniele Santilli  1 , Flavio Mozzani  1 , Michele Riva  1 , Gianluca Lucchini  1 , Alarico Ariani  1
Affiliations

bDMARDs retention rate in the biosimilar era: A real-life monocentric study

Andrea Becciolini et al. Eur J Rheumatol. 2021 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: A.B. served as a speaker for Sanofi-Genzyme, UCB, AbbVie and Amgen, outside the submitted work. The other authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
18-month drug survival of originator bDMARDs (boDMARDs) and biosimilar bDMARDs (bsDMARDs) treatment.
See this image and copyright information in PMC

References

    1. Smolen JS, Goncalves J, Quinn M, Benedetti F, Yongkwon JY. Era of biosimilars in rheumatology: Reshaping the healthcare environment. RMD Open. 2019;5:e000900. doi: 10.1136/rmdopen-2019-000900. - DOI - PMC - PubMed
    1. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165–74. doi: 10.1136/annrheumdis-2017-211937. - DOI - PubMed
    1. Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36:613–25. doi: 10.1007/s00296-016-3444-0. - DOI - PMC - PubMed
    1. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74:354–60. doi: 10.1136/annrheumdis-2013-204128. - DOI - PMC - PubMed
    1. Mok CC, Chan KY, Lee KL, Tam LS, Lee KW Hong Kong Society of Rheumatology. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: Data from the Hong Kong Biologics Registry. Int J Rheum Dis. 2014;17(Suppl 3):1–8. doi: 10.1111/1756-185X.12264. - DOI - PubMed

LinkOut - more resources